By Katherine Hamilton
Omeros shares gained Thursday after the company shared positive results for a trial of its treatment of a stem-cell transplantation complication.
The stock rose 52% to $11.15. It has nearly doubled over the past month and a half after reporting third-quarter earnings in mid-November.
The Seattle-based biopharmaceutical company said its narsoplimab treatment met its primary endpoint in a trial.
Narsoplimab is a monoclonal antibody designed to treat a complication in stem-cell transplantation called hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
The trial compared the survival rate of 28 patients with more than 100 patients in a control group who did not receive narsoplimab. Patients receiving the treatment showed significantly better survival rates.
Omeros plans to resubmit a biologics license application for its narsoplimab to the Food and Drug Administration as soon as possible, it said. If approved, narsoplimab would be the first approved treatment for TA-TMA, Omeros said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 19, 2024 10:56 ET (15:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。